|
1
|
Malpas JS: Management of multiple myeloma.
BMJ. 2:163–165. 1969. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kyle RA and Rajkumar SV: Treatment of
multiple myeloma: A comprehensive review. Clin Lymphoma Myeloma.
9:278–288. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Katz BZ: Adhesion molecules - The
lifelines of multiple myeloma cells. Semin Cancer Biol. 20:186–195.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Barlogie B, Alexanian R and Jagannath S:
Plasma cell dyscrasias. JAMA. 268:2946–2951. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Reid S, Yang S, Brown R, Kabani K, Aklilu
E, Ho PJ, Woodland N and Joshua D: Characterisation and relevance
of CD138-negative plasma cells in plasma cell myeloma. Int J Lab
Hematol. 32:e190–e196. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dimopoulos MA and Terpos E: Multiple
myeloma. Ann Oncol. 21(Suppl 7): vii143–vii150. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kyle RA: Multiple myeloma: How did it
begin? Mayo Clin Proc. 69:680–683. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kyle RA: Multiple myeloma: An odyssey of
discovery. Br J Haematol. 111:1035–1044. 2000. View Article : Google Scholar
|
|
9
|
Durie BG, Harousseau JL, Miguel JS, Bladé
J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J,
Sonneveld P, et al; International Myeloma Working Group.
International uniform response criteria for multiple myeloma.
Leukemia. 20:1467–1473. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rajkumar SV, Dimopoulos MA, Palumbo A,
Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E,
Richardson P, et al: International Myeloma Working Group updated
criteria for the diagnosis of multiple myeloma. Lancet Oncol.
15:e538–e548. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Martin NH: The immunoglobulins: A review.
J Clin Pathol. 22:117–131. 1969. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Quach H, Ritchie D, Stewart AK, Neeson P,
Harrison S, Smyth MJ and Prince HM: Mechanism of action of
immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia.
24:22–32. 2010. View Article : Google Scholar
|
|
13
|
Barlogie B, Shaughnessy J, Tricot G,
Jacobson J, Zangari M, Anaissie E, Walker R and Crowley J:
Treatment of multiple myeloma. Blood. 103:20–32. 2004. View Article : Google Scholar
|
|
14
|
Merchionne F, Perosa F and Dammacco F: New
therapies in multiple myeloma. Clin Exp Med. 7:83–97. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sonneveld P, Schoester M and de Leeuw K:
Clinical modulation of multidrug resistance in multiple myeloma:
Effect of cyclosporine on resistant tumor cells. J Clin Oncol.
12:1584–1591. 1994.PubMed/NCBI
|
|
16
|
Sonneveld P, Durie BG, Lokhorst HM, Marie
JP, Solbu G, Suciu S, Zittoun R, Löwenberg B and Nooter K; The
Leukaemia Group of the EORTC and the HOVON. Modulation of
multidrug-resistant multiple myeloma by cyclosporin. Lancet.
340:255–259. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gong J, Jaiswal R, Mathys JM, Combes V,
Grau GE and Bebawy M: Microparticles and their emerging role in
cancer multidrug resistance. Cancer Treat Rev. 38:226–234. 2012.
View Article : Google Scholar
|
|
18
|
Biedler JL and Riehm H: Cellular
resistance to actinomycin D in Chinese hamster cells in vitro:
Cross-resistance, radioautographic, and cytogenetic studies. Cancer
Res. 30:1174–1184. 1970.PubMed/NCBI
|
|
19
|
Turesson I, Velez R, Kristinsson SY and
Landgren O: Patterns of improved survival in patients with multiple
myeloma in the twenty-first century: A population-based study. J
Clin Oncol. 28:830–834. 2010. View Article : Google Scholar :
|
|
20
|
Decaux O, Lodé L, Magrangeas F, Charbonnel
C, Gouraud W, Jézéquel P, Attal M, Harousseau JL, Moreau P,
Bataille R, et al; Intergroupe Francophone du Myélome. Prediction
of survival in multiple myeloma based on gene expression profiles
reveals cell cycle and chromosomal instability signatures in
high-risk patients and hyperdiploid signatures in low-risk
patients: A study of the Intergroupe Francophone du Myélome. J Clin
Oncol. 26:4798–4805. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Garrison LP Jr, Wang ST, Huang H,
Ba-Mancini A, Shi H, Chen K, Korves C, Dhawan R, Cakana A, van de
Velde H, et al: The cost-effectiveness of initial treatment of
multiple myeloma in the U.S. with bortezomib plus melphalan and
prednisone versus thalidomide plus melphalan and prednisone or
lenalidomide plus melphalan and prednisone with continuous
lenalidomide maintenance treatment. Oncologist. 18:27–36. 2013.
View Article : Google Scholar :
|
|
22
|
Gaultney JG, Franken MG, Tan SS, Redekop
WK, Huijgens PC, Sonneveld P and Uyl-de Groot CA: Real-world health
care costs of relapsed/refractory multiple myeloma during the era
of novel cancer agents. J Clin Pharm Ther. 38:41–47. 2013.
View Article : Google Scholar
|
|
23
|
Goodwin JA, Coleman EA, Sullivan E, Easley
R, McNatt PK, Chowdhury N and Stewart CB: Personal Financial
Effects of Multiple Myeloma and Its Treatment. Cancer Nurs.
36:301–308. 2013. View Article : Google Scholar
|
|
24
|
Durie B, Binder G, Pashos C, Khan Z,
Hussein M and Borrello I: Total cost comparison in
relapsed/refractory multiple myeloma. J Med Econ. 16:614–622. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bergsagel D: The incidence and
epidemiology of plasma cell neoplasms. Stem Cells. 13(Suppl 2):
1–9. 1995.PubMed/NCBI
|
|
26
|
Chen-Kiang S: Cell-cycle control of plasma
cell differentiation and tumorigenesis. Immunol Rev. 194:39–47.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Caraux A, Klein B, Paiva B, Bret C,
Schmitz A, Fuhler GM, Bos NA, Johnsen HE, Orfao A and Perez-Andres
M; Myeloma Stem Cell Network. Circulating human B and plasma cells.
Age-associated changes in counts and detailed characterization of
circulating normal CD138− and CD138+ plasma
cells. Haematologica. 95:1016–1020. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Alessio M, Roggero S, Funaro A, De Monte
LB, Peruzzi L, Geuna M and Malavasi F: CD38 molecule: Structural
and biochemical analysis on human T lymphocytes, thymocytes, and
plasma cells. J Immunol. 145:878–884. 1990.PubMed/NCBI
|
|
29
|
Ruiz-Argüelles GJ and San Miguel JF: Cell
surface markers in multiple myeloma. Mayo Clin Proc. 69:684–690.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kara IO, Sahin B, Paydas S and Cetiner S:
Flow cytometric evaluation of bone marrow plasma cells using CD19,
CD45, CD56, CD38, and CD138 and correlation with bone marrow
infiltration ratio in multiple myeloma patients. Saudi Med J.
25:1587–1592. 2004.PubMed/NCBI
|
|
31
|
Rawstron AC: Immunophenotyping of plasma
cells. Curr Protoc Cytom. 2006.Chapter 6:Unit6.23
|
|
32
|
Bayer-Garner IB, Sanderson RD, Dhodapkar
MV, Owens RB and Wilson CS: Syndecan-1 (CD138) immunoreactivity in
bone marrow biopsies of multiple myeloma: Shed syndecan-1
accumulates in fibrotic regions. Mod Pathol. 14:1052–1058. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tokoyoda K, Hauser AE, Nakayama T and
Radbruch A: Organization of immunological memory by bone marrow
stroma. Nat Rev Immunol. 10:193–200. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Moser K, Tokoyoda K, Radbruch A, MacLennan
I and Manz RA: Stromal niches, plasma cell differentiation and
survival. Curr Opin Immunol. 18:265–270. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Vande Broek I, Vanderkerken K, Van Camp B
and Van Riet I: Extravasation and homing mechanisms in multiple
myeloma. Clin Exp Metastasis. 25:325–334. 2008. View Article : Google Scholar
|
|
36
|
Alexander DD, Mink PJ, Adami HO, Cole P,
Mandel JS, Oken MM and Trichopoulos D: Multiple myeloma: A review
of the epidemiologic literature. Int J Cancer. 120(Suppl 12):
40–61. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Brigden ML: The search for meaning in
monoclonal protein. Is it multiple myeloma or monoclonal gammopathy
of undetermined significance? Postgrad Med. 106:135–142; quiz 185.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kyle RA, Therneau TM, Rajkumar SV, Offord
JR, Larson DR, Plevak MF and Melton LJ III: A long-term study of
prognosis in monoclonal gammopathy of undetermined significance. N
Engl J Med. 346:564–569. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fonseca R, Barlogie B, Bataille R, Bastard
C, Bergsagel PL, Chesi M, Davies FE, Drach J, Greipp PR, Kirsch IR,
et al: Genetics and cytogenetics of multiple myeloma: A workshop
report. Cancer Res. 64:1546–1558. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pilarski LM and Belch AR: Circulating
monoclonal B cells expressing P glycoprotein may be a reservoir of
multidrug-resistant disease in multiple myeloma. Blood. 83:724–736.
1994.PubMed/NCBI
|
|
41
|
Bergsagel PL, Kuehl WM, Zhan F, Sawyer J,
Barlogie B and Shaughnessy J Jr: Cyclin D dysregulation: An early
and unifying pathogenic event in multiple myeloma. Blood.
106:296–303. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hundemer M, Klein U, Hose D, Raab MS,
Cremer FW, Jauch A, Benner A, Heiss C, Moos M, Ho AD, et al: Lack
of CD56 expression on myeloma cells is not a marker for poor
prognosis in patients treated by high-dose chemotherapy and is
associated with translocation t(11;14). Bone Marrow Transplant.
40:1033–1037. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chang H, Samiee S and Yi QL: Prognostic
relevance of CD56 expression in multiple myeloma: A study including
107 cases treated with high-dose melphalan-based chemotherapy and
autologous stem cell transplant. Leuk Lymphoma. 47:43–47. 2006.
View Article : Google Scholar
|
|
44
|
Van Camp B, Durie BG, Spier C, De Waele M,
Van Riet I, Vela E, Frutiger Y, Richter L and Grogan TM: Plasma
cells in multiple myeloma express a natural killer cell-associated
antigen: CD56 (NKH-1; Leu-19). Blood. 76:377–382. 1990.PubMed/NCBI
|
|
45
|
Van Riet I and Van Camp B: The involvement
of adhesion molecules in the biology of multiple myeloma. Leuk
Lymphoma. 9:441–452. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Rawstron AC, Owen RG, Davies FE, Johnson
RJ, Jones RA, Richards SJ, Evans PA, Child JA, Smith GM, Jack AS,
et al: Circulating plasma cells in multiple myeloma:
Characterization and correlation with disease stage. Br J Haematol.
97:46–55. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
O'Connell FP, Pinkus JL and Pinkus GS:
CD138 (syndecan-1), a plasma cell marker immunohistochemical
profile in hematopoietic and nonhematopoietic neoplasms. Am J Clin
Pathol. 121:254–263. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Matsui W, Huff CA, Wang Q, Malehorn MT,
Barber J, Tanhehco Y, Smith BD, Civin CI and Jones RJ:
Characterization of clonogenic multiple myeloma cells. Blood.
103:2332–2336. 2004. View Article : Google Scholar
|
|
49
|
Kyle RA and Rajkumar SV: Criteria for
diagnosis, staging, risk stratification and response assessment of
multiple myeloma. Leukemia. 23:3–9. 2009. View Article : Google Scholar :
|
|
50
|
Palumbo A, Attal M and Roussel M: Shifts
in the therapeutic paradigm for patients newly diagnosed with
multiple myeloma: Maintenance therapy and overall survival. Clin
Cancer Res. 17:1253–1263. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lonial S and Kaufman JL: Non-secretory
myeloma: a clinician's guide. Oncology (Williston Park).
27:924–930. 2013.
|
|
52
|
Cavo M, Rajkumar SV, Palumbo A, Moreau P,
Orlowski R, Bladé J, Sezer O, Ludwig H, Dimopoulos MA, Attal M, et
al; International Myeloma Working Group. International Myeloma
Working Group consensus approach to the treatment of multiple
myeloma patients who are candidates for autologous stem cell
transplantation. Blood. 117:6063–6073. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Fernández de Larrea C, Delforge M, Davies
F and Bladé J: Response evaluation and monitoring of multiple
myeloma. Expert Rev Hematol. 7:33–42. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Greipp PR, San Miguel J, Durie BG, Crowley
JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H,
Kyle RA, et al: International staging system for multiple myeloma.
J Clin Oncol. 23:3412–3420. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Hari PN, Zhang MJ, Roy V, Pérez WS, Bashey
A, To LB, Elfenbein G, Freytes CO, Gale RP, Gibson J, et al: Is the
International Staging System superior to the Durie-Salmon staging
system? A comparison in multiple myeloma patients undergoing
autologous transplant. Leukemia. 23:1528–1534. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Durie BG and Salmon SE: A clinical staging
system for multiple myeloma. Correlation of measured myeloma cell
mass with presenting clinical features, response to treatment, and
survival. Cancer. 36:842–854. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Salmon SE and Durie BG: Cellular kinetics
in multiple myeloma. A new approach to staging and treatment. Arch
Intern Med. 135:131–138. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Palumbo A, Bringhen S, Falco P, Cavallo F,
Ambrosini MT, Avonto I, Gay F, Caravita T, Bruno B and Boccadoro M:
Time to first disease progression, but not beta2-microglobulin,
predicts outcome in myeloma patients who receive thalidomide as
salvage therapy. Cancer. 110:824–829. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Hungria VT, Maiolino A, Martinez G,
Colleoni GW, Coelho EO, Rocha L, Nunes R, Bittencourt R, Oliveira
LC, Faria RM, et al; International Myeloma Working Group Latin
America. Confirmation of the utility of the International Staging
System and identification of a unique pattern of disease in
Brazilian patients with multiple myeloma. Haematologica.
93:791–792. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Kuehl WM and Bergsagel PL: Multiple
myeloma: Evolving genetic events and host interactions. Nat Rev
Cancer. 2:175–187. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
61
|
Sawyer JR: The prognostic significance of
cytogenetics and molecular profiling in multiple myeloma. Cancer
Genet. 204:3–12. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Stewart AK and Fonseca R: Prognostic and
therapeutic significance of myeloma genetics and gene expression
profiling. J Clin Oncol. 23:6339–6344. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Liebisch P and Döhner H: Cytogenetics and
molecular cytogenetics in multiple myeloma. Eur J Cancer.
42:1520–1529. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Kuehl WM and Bergsagel PL: Early genetic
events provide the basis for a clinical classification of multiple
myeloma. Hematology Am Soc Hematol Educ Program. 2005:346–352.
2005.
|
|
65
|
Pichiorri F, De Luca L and Aqeilan RI:
MicroRNAs: New players in multiple myeloma. Front Genet. 2:222011.
View Article : Google Scholar
|
|
66
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Petrocca F, Visone R, Onelli MR, Shah MH,
Nicoloso MS, de Martino I, Iliopoulos D, Pilozzi E, Liu CG, Negrini
M, et al: E2F1-regulated microRNAs impair TGFbeta-dependent
cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell.
13:272–286. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Roccaro AM, Sacco A, Thompson B, Leleu X,
Azab AK, Azab F, Runnels J, Jia X, Ngo HT, Melhem MR, et al:
MicroRNAs 15a and 16 regulate tumor proliferation in multiple
myeloma. Blood. 113:6669–6680. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Cao J, Hong CH, Rosen L, Vescio RA,
Smulson M, Lichtenstein AK and Berenson JR: Deletion of genetic
material from a poly(ADP-ribose) polymerase-like gene on chromosome
13 occurs frequently in patients with monoclonal gammopathies.
Cancer Epidemiol Biomarkers Prev. 4:759–763. 1995.PubMed/NCBI
|
|
70
|
Lopes da Silva R, Monteiro A and Veiga J:
Non-secretory multiple myeloma relapsing as extramedullary liver
plasmacytomas. J Gastrointestin Liver Dis. 20:81–83.
2011.PubMed/NCBI
|
|
71
|
Mehta J and Singhal S: Hyperviscosity
syndrome in plasma cell dyscrasias. Semin Thromb Hemost.
29:467–471. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Brown JH and Doherty CC: Renal replacement
therapy in multiple myeloma and systemic amyloidosis. Postgrad Med
J. 69:672–678. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Goldschmidt H, Lannert H, Bommer J and Ho
AD: Multiple myeloma and renal failure. Nephrol Dial Transplant.
15:301–304. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Yaccoby S: The phenotypic plasticity of
myeloma plasma cells as expressed by dedifferentiation into an
immature, resilient, and apoptosis-resistant phenotype. Clin Cancer
Res. 11:7599–7606. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Yaccoby S: Advances in the understanding
of myeloma bone disease and tumour growth. Br J Haematol.
149:311–321. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Brown R, Kabani K, Favaloro J, Yang S, Ho
PJ, Gibson J, Fromm P, Suen H, Woodland N, Nassif N, Hart D and
Joshua D: CD86+ or HLA-G+ myeloma cells are
associated with poor prognosis and once acquired by trogocytosis
create novel Tregacq cells. Blood. 120:2055–2063. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Osborne DG and Wetzel SA: Trogocytosis
results in sustained intracellular signaling in CD4(+) T cells. J
Immunol. 189:4728–4739. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Cook G: Has the T cell bitten off more
than it can chew? Blood. 120:1966–1967. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Nau KC and Lewis WD: Multiple myeloma:
Diagnosis and treatment. Am Fam Physician. 78:853–859.
2008.PubMed/NCBI
|
|
80
|
Tanaka Y1, Abe M, Hiasa M, Oda A, Amou H,
Nakano A, Takeuchi K, Kitazoe K, Kido S, Inoue D, et al: Myeloma
cell-osteoclast interaction enhances angiogenesis together with
bone resorption: a role for vascular endothelial cell growth factor
and osteopontin. Clin Cancer Res. 13:816–823. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Abe M, Hiura K, Wilde J, Shioyasono A,
Moriyama K, Hashimoto T, Kido S, Oshima T, Shibata H, Ozaki S, et
al: Osteoclasts enhance myeloma cell growth and survival via
cell-cell contact: A vicious cycle between bone destruction and
myeloma expansion. Blood. 104:2484–2491. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Hideshima T, Chauhan D, Schlossman R,
Richardson P and Anderson KC: The role of tumor necrosis factor
alpha in the pathophysiology of human multiple myeloma: Therapeutic
applications. Oncogene. 20:4519–4527. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Ge NL and Rudikoff S: Insulin-like growth
factor I is a dual effector of multiple myeloma cell growth. Blood.
96:2856–2861. 2000.PubMed/NCBI
|
|
84
|
Hideshima T and Anderson KC: Molecular
mechanisms of novel therapeutic approaches for multiple myeloma.
Nat Rev Cancer. 2:927–937. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
85
|
Brenne AT, Ro TB, Waage A, Sundan A,
Borset M and Hjorth-Hansen H: Interleukin-21 is a growth and
survival factor for human myeloma cells. Blood. 99:3756–3762. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Podar K, Tai YT, Davies FE, Lentzsch S,
Sattler M, Hideshima T, Lin BK, Gupta D, Shima Y, Chauhan D, et al:
Vascular endothelial growth factor triggers signaling cascades
mediating multiple myeloma cell growth and migration. Blood.
98:428–435. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Hideshima T, Chauhan D, Hayashi T, Podar
K, Akiyama M, Gupta D, Richardson P, Munshi N and Anderson KC: The
biological sequelae of stromal cell-derived factor-1alpha in
multiple myeloma. Mol Cancer Ther. 1:539–544. 2002.PubMed/NCBI
|
|
88
|
Sanz-Rodríguez F and Teixidó J:
VLA-4-dependent myeloma cell adhesion. Leuk Lymphoma. 41:239–245.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Michigami T, Shimizu N, Williams PJ,
Niewolna M, Dallas SL, Mundy GR and Yoneda T: Cell-cell contact
between marrow stromal cells and myeloma cells via VCAM-1 and
alpha(4) beta(1)-integrin enhances production of
osteoclast-stimulating activity. Blood. 96:1953–1960.
2000.PubMed/NCBI
|
|
90
|
Abdi J, Chen G and Chang H: Drug
resistance in multiple myeloma: Latest findings and new concepts on
molecular mechanisms. Oncotarget. 4:2186–2207. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Ogata A, Chauhan D, Teoh G, Treon SP,
Urashima M, Schlossman RL and Anderson KC: IL-6 triggers cell
growth via the Ras-dependent mitogen-activated protein kinase
cascade. J Immunol. 159:2212–2221. 1997.PubMed/NCBI
|
|
92
|
Hideshima T, Nakamura N, Chauhan D and
Anderson KC: Biologic sequelae of interleukin-6 induced PI3-K/Akt
signaling in multiple myeloma. Oncogene. 20:5991–6000. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Burger R, Le Gouill S, Tai YT,
Shringarpure R, Tassone P, Neri P, Podar K, Catley L, Hideshima T,
Chauhan D, et al: Janus kinase inhibitor INCB20 has
antiproliferative and apoptotic effects on human myeloma cells in
vitro and in vivo. Mol Cancer Ther. 8:26–35. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Kumar A, Galeb S and Djulbegovic B:
Treatment of patients with multiple myeloma: An overview of
systematic reviews. Acta Haematol. 125:8–22. 2011. View Article : Google Scholar
|
|
95
|
Andhavarapu S and Roy V: Immunomodulatory
drugs in multiple myeloma. Expert Rev Hematol. 6:69–82. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Knight R: IMiDs: A novel class of
immunomodulators. Semin Oncol. 32(Suppl 5): S24–S30. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Ludwig H, Adam Z, Tóthová E, Hajek R,
Labar B, Egyed M, Spicka I, Gisslinger H, Drach J, Kuhn I, et al:
Thalidomide maintenance treatment increases progression-free but
not overall survival in elderly patients with myeloma.
Haematologica. 95:1548–1554. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Palumbo A, Miguel JS, Sonneveld P, Moreau
P, Drach J, Morgan G and Einsele H: Lenalidomide: A new therapy for
multiple myeloma. Cancer Treat Rev. 34:283–291. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Richardson P and Anderson K: Thalidomide
and dexamethasone: A new standard of care for initial therapy in
multiple myeloma. J Clin Oncol. 24:334–336. 2006. View Article : Google Scholar
|
|
100
|
Rajkumar SV, Dispenzieri A, Fonseca R,
Lacy MQ, Geyer S, Lust JA, Kyle RA, Greipp PR, Gertz MA and Witzig
TE: Thalidomide for previously untreated indolent or smoldering
multiple myeloma. Leukemia. 15:1274–1276. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Prince HM, Schenkel B and Mileshkin L: An
analysis of clinical trials assessing the efficacy and safety of
single-agent thalidomide in patients with relapsed or refractory
multiple myeloma. Leuk Lymphoma. 48:46–55. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Cavo M, Zamagni E, Tosi P, Cellini C,
Cangini D, Tacchetti P, Testoni N, Tonelli M, de Vivo A, Palareti
G, et al: First-line therapy with thalidomide and dexamethasone in
preparation for autologous stem cell transplantation for multiple
myeloma. Haematologica. 89:826–831. 2004.PubMed/NCBI
|
|
103
|
Rajkumar SV, Blood E, Vesole D, Fonseca R
and Greipp PR; Eastern Cooperative Oncology Group. Phase III
clinical trial of thalidomide plus dexamethasone compared with
dexamethasone alone in newly diagnosed multiple myeloma: A clinical
trial coordinated by the Eastern Cooperative Oncology Group. J Clin
Oncol. 24:431–436. 2006. View Article : Google Scholar
|
|
104
|
Wu P, Davies FE, Horton C, Jenner MW,
Krishnan B, Alvares CL, Saso R, McCormack R, Dines S, Treleaven JG,
et al: The combination of cyclophosphomide, thalidomide and
dexamethasone is an effective alternative to cyclophosphamide -
vincristine - doxorubicin - methylprednisolone as induction
chemotherapy prior to autologous transplantation for multiple
myeloma: A case-matched analysis. Leuk Lymphoma. 47:2335–2338.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Dimopoulos MA, Hamilos G, Zomas A, Gika D,
Efstathiou E, Grigoraki V, Poziopoulos C, Xilouri I, Zorzou MP,
Anagnostopoulos N, et al: Pulsed cyclophosphamide, thalidomide and
dexamethasone: An oral regimen for previously treated patients with
multiple myeloma. Hematol J. 5:112–117. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
García-Sanz R, González-Fraile MI, Sierra
M, López C, González M and San Miguel JF: The combination of
thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is
feasible and can be an option for relapsed/refractory multiple
myeloma. Hematol J. 3:43–48. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Morgan GJ, Jackson GH, Davies FE, Drayson
MT, Owen RG, Gregory WM, Cohen DC, Szubert AJ, Bell SE, Ross F and
Child JA: Maintenance thalidomide may improve progression free but
not overall survival; results from the Myeloma IX Maintenance
Randomisation. Blood (ASH Annual Meeting Abstracts).
112:6562008.
|
|
108
|
Morgan GJ, Gregory WM, Davies FE, Bell SE,
Szubert AJ, Brown JM, Coy NN, Cook G, Russell NH, Rudin C, Roddie
H, Drayson MT, Owen RG, Ross FM, Jackson GH and Child JA; National
Cancer Research Institute Haematological Oncology Clinical Studies
Group. The role of maintenance thalidomide therapy in multiple
myeloma: MRC myeloma IX results and meta-analysis. Blood. 119:7–15.
2012. View Article : Google Scholar
|
|
109
|
Oakervee HE, Popat R, Curry N, Smith P,
Morris C, Drake M, Agrawal S, Stec J, Schenkein D, Esseltine DL, et
al: PAD combination therapy (PS-341/bortezomib, doxorubicin and
dexamethasone) for previously untreated patients with multiple
myeloma. Br J Haematol. 129:755–762. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Popat R, Oakervee HE, Hallam S, Curry N,
Odeh L, Foot N, Esseltine DL, Drake M, Morris C and Cavenagh JD:
Bortezomib, doxorubicin and dexamethasone (PAD) front-line
treatment of multiple myeloma: Updated results after long-term
follow-up. Br J Haematol. 141:512–516. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Mateos MV, Hernández JM, Hernández MT,
Gutiérrez NC, Palomera L, Fuertes M, Díaz-Mediavilla J, Lahuerta
JJ, de la Rubia J, Terol MJ, et al: Bortezomib plus melphalan and
prednisone in elderly untreated patients with multiple myeloma:
Results of a multicenter phase 1/2 study. Blood. 108:2165–2172.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Rajkumar SV, Hayman SR, Lacy MQ,
Dispenzieri A, Geyer SM, Kabat B, Zeldenrust SR, Kumar S, Greipp
PR, Fonseca R, et al: Combination therapy with lenalidomide plus
dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood.
106:4050–4053. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Bladé J, Samson D, Reece D, Apperley J,
Björkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S and Vesole
D; Myeloma Subcommittee of the EBMT. European Group for Blood and
Marrow Transplant. Criteria for evaluating disease response and
progression in patients with multiple myeloma treated by high-dose
therapy and haemopoietic stem cell transplantation. Br J Haematol.
102:1115–1123. 1998. View Article : Google Scholar
|
|
114
|
Alexanian R, Delasalle K, Wang M, Thomas S
and Weber D: Curability of multiple myeloma. Bone Marrow Res.
2012:9164792012. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Boccadoro M, Gavarotti P, Fossati G,
Pileri A, Marmont F, Neretto G, Gallamini A, Volta C, Tribalto M,
Testa MG, et al: Low plasma cell 3(H) thymidine incorporation in
monoclonal gammopathy of undetermined significance (MGUS),
smouldering myeloma and remission phase myeloma: A reliable
indicator of patients not requiring therapy. Br J Haematol.
58:689–696. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Brown RD, Joshua DE, Nelson M, Gibson J,
Dunn J and MacLennan IC: Serum thymidine kinase as a prognostic
indicator for patients with multiple myeloma: results from the MRC
(UK) V Trial. Br J Haematol. 84:238–241. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Lust JA, Lacy MQ, Zeldenrust SR,
Dispenzieri A, Gertz MA, Witzig TE, Kumar S, Hayman SR, Russell SJ,
Buadi FK, et al: Induction of a chronic disease state in patients
with smoldering or indolent multiple myeloma by targeting
interleukin 1{beta}-induced interleukin 6 production and the
myeloma proliferative component. Mayo Clin Proc. 84:114–122. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Joshua DE, Gibson J and Brown RD:
Mechanisms of the escape phase of myeloma. Blood Rev. 8:13–20.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Lonial S, Mitsiades CS and Richardson PG:
Treatment options for relapsed and refractory multiple myeloma.
Clin Cancer Res. 17:1264–1277. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Alexanian R, Barlogie B and Dixon D:
High-dose glucocorticoid treatment of resistant myeloma. Ann Intern
Med. 105:8–11. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
McPhedran P, Heath CW Jr and Garcia J:
Multiple myeloma incidence in metropolitan Atlanta, Georgia: Racial
and seasonal variations. Blood. 39:866–873. 1972.PubMed/NCBI
|
|
122
|
Clark DW and MacMahon B: The incidence of
multiple myeloma. J Chronic Dis. 4:508–515. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Greenberg AJ, Vachon CM and Rajkumar SV:
Disparities in the prevalence, pathogenesis and progression of
monoclonal gammopathy of undetermined significance and multiple
myeloma between blacks and whites. Leukemia. 26:609–614. 2012.
View Article : Google Scholar
|
|
124
|
Matsui W, Wang Q, Barber JP, Brennan S,
Smith BD, Borrello I, McNiece I, Lin L, Ambinder RF, Peacock C, et
al: Clonogenic multiple myeloma progenitors, stem cell properties,
and drug resistance. Cancer Res. 68:190–197. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Du J, Liu S, He J, Liu X, Qu Y, Yan W, Fan
J, Li R, Xi H, Fu W, et al: MicroRNA-451 regulates stemness of side
population cells via PI3K/Akt/mTOR signaling pathway in multiple
myeloma. Oncotarget. 6:14993–15007. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Agarwal JR and Matsui W: Multiple myeloma:
A paradigm for translation of the cancer stem cell hypothesis.
Anticancer Agents Med Chem. 10:116–120. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Pilarski LM, Mant MJ and Belch AR: Drug
resistance in multiple myeloma: Novel therapeutic targets within
the malignant clone. Leuk Lymphoma. 32:199–210. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Koskela K, Pelliniemi TT and Remes K: VAD
regimen in the treatment of resistant multiple myeloma: Slow or
fast infusion? Leuk Lymphoma. 10:347–351. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Harris AL and Hochhauser D: Mechanisms of
multidrug resistance in cancer treatment. Acta Oncol. 31:205–213.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Sonneveld P, Lokhorst HM and Vossebeld P:
Drug resistance in multiple myeloma. Semin Hematol. 34(Suppl 5):
34–39. 1997.PubMed/NCBI
|
|
131
|
Tucci M, Quatraro C, Dammacco F and
Silvestris F: Role of active drug transporters in refractory
multiple myeloma. Curr Top Med Chem. 9:218–224. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Wang JC: DNA topoisomerases. Annu Rev
Biochem. 65:635–692. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Liu LF: DNA topoisomerase poisons as
antitumor drugs. Annu Rev Biochem. 58:351–375. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Oloumi A, MacPhail SH, Johnston PJ, Banáth
JP and Olive PL: Changes in subcellular distribution of
topoisomerase IIalpha correlate with etoposide resistance in
multicell spheroids and xenograft tumors. Cancer Res. 60:5747–5753.
2000.PubMed/NCBI
|
|
135
|
Turner JG, Marchion DC, Dawson JL, Emmons
MF, Hazlehurst LA, Washausen P and Sullivan DM: Human multiple
myeloma cells are sensitized to topoisomerase II inhibitors by CRM1
inhibition. Cancer Res. 69:6899–6905. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Campling BG, Baer K, Baker HM, Lam YM and
Cole SP: Do glutathione and related enzymes play a role in drug
resistance in small cell lung cancer cell lines? Br J Cancer.
68:327–335. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Garel MC, Domenget C, Caburi-Martin J,
Prehu C, Galacteros F and Beuzard Y: Covalent binding of
glutathione to hemoglobin. I. Inhibition of hemoglobin S
polymerization. J Biol Chem. 261:14704–14709. 1986.PubMed/NCBI
|
|
138
|
Petrini M, Di Simone D, Favati A, Mattii
L, Valentini P and Grassi B: GST-pi and P-170 co-expression in
multiple myeloma. Br J Haematol. 90:393–397. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Manier S, Sacco A, Leleu X, Ghobrial IM
and Roccaro AM: Bone marrow microenvironment in multiple myeloma
progression. J Biomed Biotechnol. 2012:1574962012. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Meads MB, Gatenby RA and Dalton WS:
Environment-mediated drug resistance: A major contributor to
minimal residual disease. Nat Rev Cancer. 9:665–674. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Shain KH and Dalton WS: Cell adhesion is a
key determinant in de novo multidrug resistance (MDR): New targets
for the prevention of acquired MDR. Mol Cancer Ther. 1:69–78.
2001.
|
|
142
|
Damiano JS, Cress AE, Hazlehurst LA, Shtil
AA and Dalton WS: Cell adhesion mediated drug resistance (CAM-DR):
Role of integrins and resistance to apoptosis in human myeloma cell
lines. Blood. 93:1658–1667. 1999.PubMed/NCBI
|
|
143
|
Mitsiades CS, Treon SP, Mitsiades N, Shima
Y, Richardson P, Schlossman R, Hideshima T and Anderson KC:
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug
resistance in multiple myeloma: Therapeutic applications. Blood.
98:795–804. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Mitsiades N, Mitsiades CS, Poulaki V,
Chauhan D, Richardson PG, Hideshima T, Munshi NC, Treon SP and
Anderson KC: Apoptotic signaling induced by immunomodulatory
thalidomide analogs in human multiple myeloma cells: Therapeutic
implications. Blood. 99:4525–4530. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Chauhan D, Pandey P, Hideshima T, Treon S,
Raje N, Davies FE, Shima Y, Tai YT, Rosen S, Avraham S, et al: SHP2
mediates the protective effect of interleukin-6 against
dexamethasone-induced apoptosis in multiple myeloma cells. J Biol
Chem. 275:27845–27850. 2000.PubMed/NCBI
|
|
146
|
Hideshima T, Richardson P, Chauhan D,
Palombella VJ, Elliott PJ, Adams J and Anderson KC: The proteasome
inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes
drug resistance in human multiple myeloma cells. Cancer Res.
61:3071–3076. 2001.PubMed/NCBI
|
|
147
|
Dalton WS and Jove R: Drug resistance in
multiple myeloma: Approaches to circumvention. Semin Oncol.
26(Suppl 13): 23–27. 1999.PubMed/NCBI
|
|
148
|
Mitsiades CS, Mitsiades N, Poulaki V,
Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi
NC, Richardson PG, et al: Activation of NF-kappaB and upregulation
of intracellular anti-apoptotic proteins via the IGF-1/Akt
signaling in human multiple myeloma cells: Therapeutic
implications. Oncogene. 21:5673–5683. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Hideshima T, Chauhan D, Richardson P,
Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A,
Palombella V, et al: NF-kappa B as a therapeutic target in multiple
myeloma. J Biol Chem. 277:16639–16647. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Nefedova Y, Landowski TH and Dalton WS:
Bone marrow stromal-derived soluble factors and direct cell contact
contribute to de novo drug resistance of myeloma cells by distinct
mechanisms. Leukemia. 17:1175–1182. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Kühne A, Tzvetkov MV, Hagos Y, Lage H,
Burckhardt G and Brockmöller J: Influx and efflux transport as
determinants of melphalan cytotoxicity: Resistance to melphalan in
MDR1 over-expressing tumor cell lines. Biochem Pharmacol. 78:45–53.
2009. View Article : Google Scholar
|
|
152
|
Doyle L and Ross DD: Multidrug resistance
mediated by the breast cancer resistance protein BCRP (ABCG2).
Oncogene. 22:7340–7358. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Raaijmakers HG, Izquierdo MA, Lokhorst HM,
de Leeuw C, Belien JA, Bloem AC, Dekker AW, Scheper RJ and
Sonneveld P: Lung-resistance-related protein expression is a
negative predictive factor for response to conventional low but not
to intensified dose alkylating chemotherapy in multiple myeloma.
Blood. 91:1029–1036. 1998.PubMed/NCBI
|
|
154
|
Hofmeister CC, Yang X, Pichiorri F, Chen
P, Rozewski DM, Johnson AJ, Lee S, Liu Z, Garr CL, Hade EM, et al:
Phase I trial of lenalidomide and CCI-779 in patients with relapsed
multiple myeloma: Evidence for lenalidomide-CCI-779 interaction via
P-glycoprotein. J Clin Oncol. 29:3427–3434. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Tong Z, Yerramilli U, Surapaneni S and
Kumar G: The interactions of lenalidomide with human uptake and
efflux transporters and UDP-glucuronosyltransferase 1A1: Lack of
potential for drug-drug interactions. Cancer Chemother Pharmacol.
73:869–874. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Jiang Y: Pharmacokinetic and
pharmacodynamic studies of lenalidomide and pomalidomide.
Electronic Thesis or Dissertation. Retrieved from https://etd.ohiolink.edu/.
|
|
157
|
O'Connor R, Ooi MG, Meiller J, Jakubikova
J, Klippel S, Delmore J, Richardson P, Anderson K, Clynes M,
Mitsiades CS, et al: The interaction of bortezomib with multidrug
transporters: Implications for therapeutic applications in advanced
multiple myeloma and other neoplasias. Cancer Chemother Pharmacol.
71:1357–1368. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Nakamura T, Tanaka K, Matsunobu T, Okada
T, Nakatani F, Sakimura R, Hanada M and Iwamoto Y: The mechanism of
cross-resistance to proteasome inhibitor bortezomib and overcoming
resistance in Ewing's family tumor cells. Int J Oncol. 31:803–811.
2007.PubMed/NCBI
|
|
159
|
Zimmermann C, Gutmann H and Drewe J:
Thalidomide does not interact with P-glycoprotein. Cancer Chemother
Pharmacol. 57:599–606. 2006. View Article : Google Scholar
|
|
160
|
Dilger K, Alberer M, Busch A, Enninger A,
Behrens R, Koletzko S, Stern M, Beckmann C and Gleiter CH:
Pharmacokinetics and pharmacodynamic action of budesonide in
children with Crohn's disease. Aliment Pharmacol Ther. 23:387–396.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Karssen AM, Meijer OC, van der Sandt IC,
De Boer AG, De Lange EC and De Kloet ER: The role of the efflux
transporter P-glycoprotein in brain penetration of prednisolone. J
Endocrinol. 175:251–260. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Shapiro AB and Ling V: Positively
cooperative sites for drug transport by P-glycoprotein with
distinct drug specificities. Eur J Biochem. 250:130–137. 1997.
View Article : Google Scholar
|
|
163
|
Cole SP and Deeley RG: Transport of
glutathione and glutathione conjugates by MRP1. Trends Pharmacol
Sci. 27:438–446. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Robey RW, Shukla S, Finley EM, Oldham RK,
Barnett D, Ambudkar SV, Fojo T and Bates SE: Inhibition of
P-glycoprotein (ABCB1)- and multidrug resistance-associated protein
1 (ABCC1)-mediated transport by the orally administered inhibitor,
CBT-1((R)). Biochem Pharmacol. 75:1302–1312. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Kitazono M, Sumizawa T, Takebayashi Y,
Chen ZS, Furukawa T, Nagayama S, Tani A, Takao S, Aikou T and
Akiyama S: Multidrug resistance and the lung resistance-related
protein in human colon carcinoma SW-620 cells. J Natl Cancer Inst.
91:1647–1653. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Kang W and Weiss M: Digoxin uptake,
receptor heterogeneity, and inotropic response in the isolated rat
heart: A comprehensive kinetic model. J Pharmacol Exp Ther.
302:577–583. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Abbaszadegan MR, Futscher BW, Klimecki WT,
List A and Dalton WS: Analysis of multidrug resistance-associated
protein (MRP) messenger RNA in normal and malignant hematopoietic
cells. Cancer Res. 54:4676–4679. 1994.PubMed/NCBI
|
|
168
|
Duhem C, Ries F and Dicato M: What does
multidrug resistance (MDR) expression mean in the clinic?
Oncologist. 1:151–158. 1996.PubMed/NCBI
|
|
169
|
Pilarski LM and Belch AR: Intrinsic
expression of the multidrug transporter, P-glycoprotein 170, in
multiple myeloma: Implications for treatment. Leuk Lymphoma.
17:367–374. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Nuessler V, Gieseler F, Gullis E,
Pelka-Fleischer R, Stötzer O, Zwierzina H and Wilmanns W:
Functional P-gp expression in multiple myeloma patients at primary
diagnosis and relapse or progressive disease. Leukemia. 11(Suppl
5): S10–S14. 1997.
|
|
171
|
Drain S, Flannely L, Drake MB, Kettle P,
Orr N, Bjourson AJ, Catherwood MA and Alexander HD: Multidrug
resistance gene expression and ABCB1 SNPs in plasma cell myeloma.
Leuk Res. 35:1457–1463. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Li YH, Wang YH, Li Y and Yang L: MDR1 gene
polymorphisms and clinical relevance. Yi Chuan Xue Bao. 33:93–104.
2006.PubMed/NCBI
|
|
173
|
Drain S, Catherwood MA, Orr N, Galligan L,
Rea IM, Hodkinson C, Drake MB, Kettle PJ, Morris TC and Alexander
HD: ABCB1 (MDR1) rs1045642 is associated with increased overall
survival in plasma cell myeloma. Leuk Lymphoma. 50:566–570. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Buda G, Maggini V, Galimberti S, Martino
A, Giuliani N, Morabito F, Genestreti G, Iacopino P, Rizzoli V,
Barale R, et al: MDR1 polymorphism influences the outcome of
multiple myeloma patients. Br J Haematol. 137:454–456. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Barrand MA, Bagrij T and Neo SY: Multidrug
resistance-associated protein: A protein distinct from
P-glycoprotein involved in cytotoxic drug expulsion. Gen Pharmacol.
28:639–645. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Davey RA, Longhurst TJ, Davey MW, Belov L,
Harvie RM, Hancox D and Wheeler H: Drug resistance mechanisms and
MRP expression in response to epirubicin treatment in a human
leukaemia cell line. Leuk Res. 19:275–282. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Versantvoort CH, Broxterman HJ, Bagrij T,
Scheper RJ and Twentyman PR: Regulation by glutathione of drug
transport in multidrug-resistant human lung tumour cell lines
overexpressing multidrug resistance-associated protein. Br J
Cancer. 72:82–89. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Buda G, Ricci D, Huang CC, Favis R, Cohen
N, Zhuang SH, Harousseau JL, Sonneveld P, Bladé J and Orlowski RZ:
Polymorphisms in the multiple drug resistance protein 1 and in
P-glycoprotein 1 are associated with time to event outcomes in
patients with advanced multiple myeloma treated with bortezomib and
pegylated liposomal doxorubicin. Ann Hematol. 89:1133–1140. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Grant CE, Valdimarsson G, Hipfner DR,
Almquist KC, Cole SP and Deeley RG: Overexpression of multidrug
resistance-associated protein (MRP) increases resistance to natural
product drugs. Cancer Res. 54:357–361. 1994.PubMed/NCBI
|
|
180
|
Lehne G: P-glycoprotein as a drug target
in the treatment of multidrug resistant cancer. Curr Drug Targets.
1:85–99. 2000. View Article : Google Scholar
|
|
181
|
Bart J, Hollema H, Groen HJ, de Vries EG,
Hendrikse NH, Sleijfer DT, Wegman TD, Vaalburg W and van der Graaf
WT: The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and
MRP2, in the normal blood-testis barrier and in primary testicular
tumours. Eur J Cancer. 40:2064–2070. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Cooray HC, Blackmore CG, Maskell L and
Barrand MA: Localisation of breast cancer resistance protein in
microvessel endothelium of human brain. Neuroreport. 13:2059–2063.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Xu J, Liu Y, Yang Y, Bates S and Zhang JT:
Characterization of oligomeric human half-ABC transporter
ATP-binding cassette G2. J Biol Chem. 279:19781–19789. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Raaijmakers MH, de Grouw EP, Heuver LH,
van der Reijden BA, Jansen JH, Scheffer G, Scheper RJ, de Witte TJ
and Raymakers RA: Impaired breast cancer resistance protein
mediated drug transport in plasma cells in multiple myeloma. Leuk
Res. 29:1455–1458. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Doyle LA, Yang W, Abruzzo LV, Krogmann T,
Gao Y, Rishi AK and Ross DD: A multidrug resistance transporter
from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA.
95:15665–15670. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Jakubikova J, Adamia S, Kost-Alimova M,
Klippel S, Cervi D, Daley JF, Cholujova D, Kong SY, Leiba M, Blotta
S, et al: Lenalidomide targets clonogenic side population in
multiple myeloma: Pathophysiologic and clinical implications.
Blood. 117:4409–4419. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Turner JG, Gump JL, Zhang C, Cook JM,
Marchion D, Hazlehurst L, Munster P, Schell MJ, Dalton WS and
Sullivan DM: ABCG2 expression, function, and promoter methylation
in human multiple myeloma. Blood. 108:3881–3889. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Tamura A, Wakabayashi K, Onishi Y, Takeda
M, Ikegami Y, Sawada S, Tsuji M, Matsuda Y and Ishikawa T:
Re-evaluation and functional classification of non-synonymous
single nucleotide polymorphisms of the human ATP-binding cassette
transporter ABCG2. Cancer Sci. 98:231–239. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Izquierdo MA, Scheffer GL, Flens MJ,
Shoemaker RH, Rome LH and Scheper RJ: Relationship of LRP-human
major vault protein to in vitro and clinical resistance to
anticancer drugs. Cytotechnology. 19:191–197. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Feller N, Kuiper CM, Lankelma J, Ruhdal
JK, Scheper RJ, Pinedo HM and Broxterman HJ: Functional detection
of MDR1/P170 and MRP/P190-mediated multidrug resistance in tumour
cells by flow cytometry. Br J Cancer. 72:543–549. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Sherry ST, Ward MH, Kholodov M, Baker J,
Phan L, Smigielski EM and Sirotkin K: dbSNP: The NCBI database of
genetic variation. Nucleic Acids Res. 29:308–311. 2001. View Article : Google Scholar :
|
|
192
|
Henríquez-Hernández LA, Moreno M, Rey A,
Lloret M and Lara PC: MVP expression in the prediction of clinical
outcome of locally advanced oral squamous cell carcinoma patients
treated with radiotherapy. Radiat Oncol. 7:1–6. 2012. View Article : Google Scholar
|
|
193
|
Litviakov NV, Cherdyntseva NV, Tsyganov
MM, Denisov EV, Garbukov EY, Merzliakova MK, Volkomorov VV,
Vtorushin SV, Zavyalova MV, Slonimskaya EM, et al: Changing the
expression vector of multidrug resistance genes is related to
neoadjuvant chemotherapy response. Cancer Chemother Pharmacol.
71:153–163. 2013. View Article : Google Scholar
|
|
194
|
van den Heuvel-Eibrink MM, Sonneveld P and
Pieters R: The prognostic significance of membrane
transport-associated multidrug resistance (MDR) proteins in
leukemia. Int J Clin Pharmacol Ther. 38:94–110. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Herlevsen M, Oxford G, Owens CR, Conaway M
and Theodorescu D: Depletion of major vault protein increases
doxorubicin sensitivity and nuclear accumulation and disrupts its
sequestration in lysosomes. Mol Cancer Ther. 6:1804–1813. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Sikic BI, Fisher GA, Lum BL, Halsey J,
Beketic-Oreskovic L and Chen G: Modulation and prevention of
multidrug resistance by inhibitors of P-glycoprotein. Cancer
Chemother Pharmacol. 40(Suppl 1): S13–S19. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Sikic BI: Pharmacologic approaches to
reversing multidrug resistance. Semin Hematol. 34(Suppl 5): 40–47.
1997.PubMed/NCBI
|
|
198
|
Yang HH, Ma MH, Vescio RA and Berenson JR:
Overcoming drug resistance in multiple myeloma: The emergence of
therapeutic approaches to induce apoptosis. J Clin Oncol.
21:4239–4247. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Fisher GA, Lum BL, Hausdorff J and Sikic
BI: Pharmacological considerations in the modulation of multidrug
resistance. Eur J Cancer. 32A:1082–1088. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
200
|
Dalton W and Lehnert M: Dexverapamil: A
clinical approach to circumvention of multidrug resistance. J
Cancer Res Clin Oncol. 121:R1. 1995. View Article : Google Scholar
|
|
201
|
Berenson JR, Crowley JJ, Grogan TM,
Zangmeister J, Briggs AD, Mills GM, Barlogie B and Salmon SE:
Maintenance therapy with alternate-day prednisone improves survival
in multiple myeloma patients. Blood. 99:3163–3168. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
202
|
Urashima M, Chen BP, Chen S, Pinkus GS,
Bronson RT, Dedera DA, Hoshi Y, Teoh G, Ogata A, Treon SP, et al:
The development of a model for the homing of multiple myeloma cells
to human bone marrow. Blood. 90:754–765. 1997.PubMed/NCBI
|
|
203
|
Brown R, Suen H, Favaloro J, Yang S, Ho
PJ, Gibson J and Joshua D: Trogocytosis generates acquired
regulatory T cells adding further complexity to the dysfunctional
immune response in multiple myeloma. OncoImmunology. 1:1658–1660.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
204
|
Duffy MJ: Serum tumor markers in breast
cancer: Are they of clinical value? Clin Chem. 52:345–351. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Allin KH, Nordestgaard BG, Flyger H and
Bojesen SE: Elevated pre-treatment levels of plasma C-reactive
protein are associated with poor prognosis after breast cancer: A
cohort study. Breast Cancer Res. 13:R552011. View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Guo L, Abraham J, Flynn DC, Castranova V,
Shi X and Qian Y: Individualized survival and treatment response
predictions for breast cancers using phospho-EGFR, phospho-ER,
phospho-HER2/neu, phospho-IGF-IR/In, phospho-MAPK, and
phospho-p70S6K proteins. Int J Biol Markers. 22:1–11.
2007.PubMed/NCBI
|
|
207
|
Sargent DJ, Conley BA, Allegra C and
Collette L: Clinical trial designs for predictive marker validation
in cancer treatment trials. J Clin Oncol. 23:2020–2027. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Kumar G, Lau H and Laskin O: Lenalidomide:
In vitro evaluation of the metabolism and assessment of cytochrome
P450 inhibition and induction. Cancer Chemother Pharmacol.
63:1171–1175. 2009. View Article : Google Scholar
|
|
209
|
Lampen A, Zhang Y, Hackbarth I, Benet LZ,
Sewing KF and Christians U: Metabolism and transport of the
macrolide immunosuppressant sirolimus in the small intestine. J
Pharmacol Exp Ther. 285:1104–1112. 1998.PubMed/NCBI
|
|
210
|
Sattler M, Guengerich FP, Yun CH,
Christians U and Sewing KF: Cytochrome P-450 3A enzymes are
responsible for biotransformation of FK506 and rapamycin in man and
rat. Drug Metab Dispos. 20:753–761. 1992.PubMed/NCBI
|
|
211
|
Joshua DE, Brown RD and Gibson J: Multiple
myeloma: Why does the disease escape from plateau phase? Br J
Haematol. 88:667–671. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
212
|
Fung KL and Gottesman MM: A synonymous
polymorphism in a common MDR1 (ABCB1) haplotype shapes protein
function. Biochim Biophys Acta. 1794:860–871. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
213
|
Hoffmeyer S, Burk O, von Richter O, Arnold
HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I,
Eichelbaum M, et al: Functional polymorphisms of the human
multidrug-resistance gene: Multiple sequence variations and
correlation of one allele with P-glycoprotein expression and
activity in vivo. Proc Natl Acad Sci USA. 97:3473–3478. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
214
|
Dumontet C, Landi S, Reiman T, Perry T,
Plesa A, Bellini I, Barale R, Pilarski LM, Troncy J, Tavtigian S,
et al: Genetic polymorphisms associated with outcome in multiple
myeloma patients receiving high-dose melphalan. Bone Marrow
Transplant. 45:1316–1324. 2010. View Article : Google Scholar
|
|
215
|
Maggini V, Buda G, Martino A, Presciuttini
S, Galimberti S, Orciuolo E, Barale R, Petrini M and Rossi AM: MDR1
diplotypes as prognostic markers in multiple myeloma. Pharmacogenet
Genomics. 18:383–389. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
216
|
Natarajan K, Xie Y, Baer MR and Ross DD:
Role of breast cancer resistance protein (BCRP/ABCG2) in cancer
drug resistance. Biochem Pharmacol. 83:1084–1103. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
217
|
Dispenzieri A, Kyle R, Merlini G, Miguel
JS, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S,
et al; International Myeloma Working Group. International Myeloma
Working Group guidelines for serum-free light chain analysis in
multiple myeloma and related disorders. Leukemia. 23:215–224. 2009.
View Article : Google Scholar
|
